^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
HER2 Negative Breast Cancer: Invasive Breast Cancer…SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE (IV) M1 DISEASE…HER2-Negative…Other Recommended Regimens…Epirubicin
Source:
Title:
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Excerpt:
...- Patients must have histologically confirmed estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) negative carcinoma of the breast that is metastatic or unresectable and for which standard curative or palliative measures do...
Trial ID:
Source:
Title:
A Real-World Study of the Efficacy and Safety of Liposomal Doxorubicin Versus Epirubicin in AC-T Regimen for Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer
Excerpt:
...Histopathologically diagnosed as unilateral or bilateral HER2-negative, invasive breast cancer; 2. ...
Trial ID:
More C2 evidence
Source:
Title:
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. Ensayo aleatorizado, fase III, de terapia endocrina adyuvante estándar +/- quimioterapia en pacientes con cáncer de mama positivo para receptores hormonales y negativo para HER2 con afectación de 1 a 3 ganglios y con un Recurrence Score (RS) de 25 o inferior.
Excerpt:
...Patients must have a histologically confirmed diagnosis of node positive (1-3 nodes)invasive breast carcinoma with positive estrogen and/or progesterone receptor status,and negative HER-2, as determined by IHC or non-amplified FISH or CISH for screening.2. ...
Trial ID:
